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Abstract
Introduction: Inappropriate use of antibiotics is common in healthcare settings, with urinary tract
infections (UTI) being one of the most common indications for antibiotic prescriptions. This
study evaluated the appropriateness of oral antibiotic therapy among adult patients with
suspected UTI who were admitted to Yale New Haven Hospital during January 2018. We
hypothesized that 60% of antibiotics were inappropriate, and that inappropriate therapy was
associated with Clostridioides difficile infection, hospital readmission and/or mortality.
Methods: We conducted a retrospective cohort study of adult patients who were admitted to Yale
New Haven Hospital from January 1, 2018 to January 31, 2018. Data was collected from the
electronic medical record system Epic, and records were reviewed to collect demographics,
microbiology data, and antibiotics administered.
Results: Among 312 eligible patients (median age= 77 years), only 37 had a UTI according to
CDC definitions, where only 12 of those received antibiotics for 7 days or less. The duration of
antibiotics was inappropriate for approximately 40% of the time. In total, 263 (95.64%) received
inappropriate antibiotic therapy. The most common organisms were Escherichia coli (49.08%),
Klebsiella species (17.18%), and Proteus species (11.66%). Among patients who received
antibiotics (n=275, 88.14%), the most common choice during and after hospitalization was
cephalosporin. While there were no significant differences in adverse drug events between the
groups that received inappropriate and appropriate therapy, all 3 patients with Clostridioides
difficile infections received inappropriate antibiotics.
Conclusion: The high percentage of inappropriate antibiotic therapy indicates a greater need for
improved antibiotic therapy measures and suggests the importance of interventions such as
antibiotic stewardship programs.
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Introduction
Antibiotic resistance is a major global threat and contributes to approximately 33,000
deaths and 874,500 disability-adjusted life years per year.1 In May 2015, the World Health
Organization adopted a global action plan to address its growing burden, yet antibiotic resistance
still maintains a problem with severe health and economic consequences.2 Modelling studies
expect a range of $14 billion to $3 trillion loss to global gross domestic product by 2050 from
resistance microbes, and in the United States, methicillin-resistant Staphylococcus aureus
(MRSA) infection can cost $20,000 per case to $7 billion for community-acquired MRSA.3
One factor that contributes to the high prevalence of antibiotic resistance is the
inappropriate use of antibiotics in healthcare settings.4 Prolonged antibiotic therapy is
significantly associated with adverse drug events (ADE), and approximately 20% of adult
inpatients experience at least one ADE, with a 3% increased risk of an ADE every ten additional
days.5 Urinary tract infection (UTI) is one of the most common indications for antibiotic
prescriptions, and inappropriate antibiotic treatment during hospitalization has been shown to be
very common.6, 7 The recommended guidelines of antibiotic therapy for UTI is up to 7 days
depending on the antibiotic prescription, although complicated UTI takes longer duration.7
Longer treatment durations do not provide added benefit, and the risks involved in
overprescribing antibiotics have encouraged a new antibiotic manta, “Shorter is Better.”8
There has been increased scrutiny regarding the appropriateness of antibiotic continuation
following hospital discharge. For oral antibiotics, approximately 60 percent of the antibiotic
treatment duration occurs after hospital discharge, exceeding the national guidelines for median
total antibiotic duration.9 Patients with UTI have similarly high percentages of inappropriate
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antibiotic treatment duration when including outpatient therapy, with recent study findings
between 50% and greater than 75%.7, 10
The objectives of this study were to evaluate the appropriateness of antibiotic therapy for
UTI among adults before and after hospital discharge by identifying the proportion of
inappropriate oral antibiotic prescriptions and by examining the relationship between
inappropriate prescription and the occurrence of Clostridioides difficile infection, hospital
readmission, and/or all-cause mortality within 90 days of discharge. Patients who did not have a
UTI according to CDC definitions but received antibiotics were considered to have incorrect
indication.11 Total treatment duration was considered inappropriate if the total treatment duration
exceeded 7 days, or 14 days for patients with costovertebral angle pain or tenderness.12
Inappropriate antibiotic therapy was defined in this paper as patients with incorrect indication
and/or inappropriate duration. Patients without UTI but who received antibiotics, and patients
with UTI who received no antibiotics were considered to receive neither appropriate nor
inappropriate antibiotic therapy, and was excluded from any assessments for antibiotic duration
and adverse drug events. We hypothesized that 60% of hospitalizations in which oral antibiotics
were prescribed for suspected UTI involve inappropriate prescriptions for oral antibiotics and
that inappropriate therapy was associated with Clostridioides difficile infection, hospital
readmission and/or mortality.
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Methods
We conducted a retrospective cohort study of adult patients who were admitted to Yale
New Haven Hospital, a 1541-bed tertiary care center in New Haven, Connecticut, from January
1, 2018 to January 31, 2018. Patients were included in the data collection if the patients were 18
years or older, had either a UTI or sepsis flag by International Classification of Diseases, Tenth
Revision (ICD-10) codes, and stayed in the hospital for 14 days or less. Only the first admission
to the hospital during the 2018 calendar year was considered. Exclusion criteria involved
hospitalization at any hospital within the Yale New Haven Health System in the 90 days prior to
admission, certain discharge floors, solid or liquid tumor transplant recipient, active pregnancy,
admission for urologic procedure, presence of ileal conduit or nephrostomy tube, neutrophils less
than 1000 at any time during admission, and neutropenic fever. The Yale Human Investigation
Committee approved this study.
For all patients, we collected demographics, hospitalization information, microbiology
data, and antibiotics administered. Hospitalization information included admission and discharge
dates and dates of admission to an intensive care unit. Microbiology data and antibiotic
administration were collected during hospitalization and 90-day post discharge. Comorbidities,
susceptibility or resistance of antibiotics, and missing antibiotics and their dates of
administration were ascertained from medical record review. Antibiotic groups included
aminoglycosides, carbapenems, cephalosporins, clindamycin, glycopeptides, macrolides,
metronidazole, nitrofurantoin, oxazolidinones, penicillins, polymyxins, quinolones, sulfonamides
and trimethoprim, and tetracyclines. Antibiotics administered orally were evaluated. Topical,
vaginal, ophthalmic, otic, and nasal antibiotics were excluded.
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Patients who were diagnosed with sepsis but did not have a urine culture were manually
excluded. The remaining patients’ charts were reviewed to determine whether the patients met
UTI criteria according to CDC definitions.11 Patients were also classified as having
asymptomatic bacteriuria, at least one symptom with urine culture of 10,000-100,000 CFU/mL,
at least one symptoms with urine culture of 100,000+ CFU/mL, and no symptoms with urine
culture less than 100,000 CFU/mL. Asymptomatic bacteriuria was defined as at least one urine
culture with 100,000 CFU/mL in a patient who had no signs or symptoms of a UTI.13 Patient
characteristics were calculated as the percentage of total eligible patients with the specified
attribute. Microbiological data was stratified by type of culture. All analysis was performed
using R version 3.6.2 software.
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Results
Patient Characteristics
We identified 315 patients who had either a UTI flag or a sepsis flag. Of these patients, 3
were excluded because they did not have a urine culture. 161 patients did not have growth in
their urine cultures, and of the remaining 151, only 37 (11.86%) met CDC definitions of UTI.
The other patients had asymptomatic bacteriuria (n=60, 19.23%), at least one symptom with
urine culture of 10,000-100,000 CFU/mL (n=10, 3.21%), at least one symptom with urine
culture of 100,000+ CFU/mL (n=23, 7.37%), or no symptoms with urine culture less than
100,000 CFU/mL (n=21, 6.73%). 3 patients had costovertebral angle pain or tenderness, but
none of them met UTI criteria. Table 1 summarizes patient characteristics of the remaining 312
patients included in the analysis. Median age was 77 years (range 63.75-86 years), and there
were more females (n=188, 60.26%). The most common comorbidities were hypertension,
diabetes, and coronary artery disease. 40.43% of all patients’ comorbidities were cardiovascular,
with the next 2 most common comorbidity categories relating to endocrinology (13.73%) and
neurology (11.55%). The mean LOS was 5.0 days (IQR: 3.0-7.0 days).

Microbiology Data
Of the 315 urine cultures collected from 312 patients, 163 isolates were identified (Table
2). The most common organisms were Escherichia coli (49.08%), Klebsiella species (17.18%),
and Proteus species (11.66%). Figure 1 shows antimicrobial susceptibilities for all cultures and
for the subset Escherichia coli. Among all urine isolates, 60 (36.81%) were ampicillinsusceptible, 106 (65.03%) were cefazolin-susceptible, 112 (68.71%) were ceftriaxone-

Yoo 9
susceptible, 103 (63.19%) were ciprofloxacin-susceptible, 103 (63.19%) were nitrofurantoinsusceptible, and 114 (69.94%) were trimethoprim/sulfamethoxazole-susceptible. For these
isolates, 79 (48.47%) were ampicillin-resistant, 23 (14.11%) were cefazolin-resistant, 17
(10.43%) were ceftriaxone-resistant, 35 (21.47%) were ciprofloxacin-resistant, 32 (19.63%) were
nitrofurantoin resistant, and 31 (19.02%) were trimethoprim/sulfamethoxazole-resistant. Among
80 Escherichia coli isolates, 38 (47.50%) were ampicillin-susceptible, 67 (83.75%) were
cefazolin-susceptible, 73 (91.25%) were ceftriaxone-susceptible, 57 (71.25%) were
ciprofloxacin-susceptible, 74 (92.50%) were nitrofurantoin-susceptible, and 63 (78.75%) were
trimethoprim/sulfamethoxazole-susceptible. 41 (51.25%) were ampicillin-resistant, 13 (16.25%)
were cefazolin-resistant, 7 (8.75%) were ceftriaxone-resistant, 23 (28.75%) were ciprofloxacinresistant, 3 (3.75%) were nitrofurantoin-resistant, and 17 (21.25%) were
trimethoprim/sulfamethoxazole-resistant.

Antibiotic Use
Table 3 provides a list of most common medications during admission and after
discharge. The most common choice during and after hospitalization was cephalosporin. The
next common choices during hospitalization included tetracycline and vancomycin, while the
common choices after discharge included fluoroquinolones and penicillin. Overall, 275 patients
(88.14%) received at least one antibiotic during or after hospitalization. In total, 161 patients
(58.55%) did not have growth in their urine culture, 21 patients (7.64%) had no symptoms and a
urine culture of less than 100,000 CFU/mL, 60 patients (21.82%) had asymptomatic bacteriuria,
10 patients (3.64%) had a urine culture between 10,000 and 100,000 CFU/mL with at least one
symptom, 23 patients (8.36%) had a urine culture of greater than 100,000 CFU/mL with at least
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one symptom, and 37 patients (13.45%) were determined to have UTI according to CDC
definitions. Of the patients who did not receive antibiotics, 28 patients had no growth in their
urine culture, 4 patients had no symptoms with a urine culture of less than 100,000 CFU/mL, 1
patient had asymptomatic bacteriuria, and 4 patients had UTI. The 37 patients who did not
receive any antibiotic were not included in Table 4 that shows antibiotic duration during
hospitalization and post discharge. The median of patients who had a UTI received 9 days of
antibiotics (IQR: 7, 15), while that of patients with no growth in urine cultures received 5 days of
antibiotics (IQR: 3, 8). 105 patients (38.18%) either exceeded 7 days for typical UTI or 14 days
for UTI with costovertebral angle pain or tenderness. 21 out of 33 patients with UTI received
inappropriate duration; therefore, only 12 patients (4.36%) received appropriate antibiotic
therapy with correct indication. In total, 263 (95.64%) received inappropriate therapy. The
duration median for patients with appropriate therapy was 6.5 (IQR: 6, 7), while the duration
median for patients with inappropriate therapy was 7 (IQR: 4, 10).

Adverse Drug Events
Laboratory testing for Clostridioides difficile testing was performed in 29 patients, and 3
patients were positive for Clostridioides difficile infection (asymptomatic bacteriuria n=2, no
growth in urine culture n=1). All 3 infections occurred among patients who received
inappropriate antibiotics (Table 5). Re-admissions for patients with appropriate therapy was
higher than those with inappropriate therapy (50% vs. 39.92%), but mortality was higher among
patients with inappropriate therapy (9.89% vs. 8.33%).
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Discussion
Our study found that most (95.64%) oral antibiotic prescriptions for patients with
suspected UTI were inappropriate. Of the 275 patients who received antibiotics, only 37 patients
had a correct indication for UTI and 170 (61.82%) received antibiotics for 7 days or less, or 14
days if there was costovertebral angle gain or tenderness. In total, only 12 patients had correct
indication and correct duration. The inappropriateness percentage is very high, but the results
support previous studies that the majority of patients are treated inappropriately for UTI.7, 14
While the 95.64% inappropriateness is higher than the results of past studies, it is important to
note that the median age was 77 with an interquartile range from 63.75 to 86, and antibiotics may
have been administered for age-related diseases other than for UTI. For adverse drug events, readmission for patients with appropriate therapy was higher than those with inappropriate therapy,
but mortality was higher among patients with inappropriate therapy. None of the adverse drug
events showed significant differences between the appropriate and inappropriate groups.
However, the 3 Clostridioides difficile infections, all of which occurred among patients with
inappropriate therapy, may be noteworthy and interesting to study in greater depth.
There were a few limitations to this study. The study looked at medical charts of patients
from the first month of 2018, so there were a limited number of patients. Given that 37 patients
did not receive antibiotics, the total number eligible for the study was small. Second, the study
was conducted only with medical chart review, and because the medical charts were not
extensive, it was often times unclear whether the antibiotics were used to treat UTI or another
cause. This was a problem especially in reviewing outpatient antibiotic prescriptions, as some
medication start and end dates spanned months until the patients’ next emergency department
visit. It was uncertain whether the patient took antibiotics for the entire time, or whether patients’
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medical charts were not updated. While days of antibiotics were removed when the chart reviews
clearly indicated an error, there were still a few patients with high number of antibiotic days
which may overestimate the results. Nevertheless, the study fulfills a knowledge gap about
indication and duration of prescription therapy for patients with UTI. The duration median for
patients with appropriate therapy was 6.5 days (IQR: 6, 7), while the duration median for patients
with inappropriate therapy was 7 (IQR: 4, 10). While the median is not very different between
the two groups, the wider interquartile range for the latter is aligned with the notion that patients
in the inappropriate therapy category tend to have less consistent treatment durations.
The high percentage of inappropriate antibiotic therapy suggests a need for greater
quality improvement in antibiotic therapy decision-making processes at Yale New Haven
Hospital and other hospitals. Antibiotic stewardship may be one effective intervention to
optimize outpatient therapy, as former studies found improvement in appropriate selection and
timing of therapy after the implementation of stewardship programs.15, 16 Further areas of
research should evaluate the relationship between inappropriate antibiotic therapy and adverse
drug events for patients with UTI as well as other diseases. Interventions such as antibiotic
stewardship should also be explored, as stewardship programs have been shown to reduce the
percentage of inappropriate antibiotic therapy among patients with suspected urinary tract
infection. Interventions such as antibiotic stewardship programs should particularly evaluate post
discharge prescriptions in order to ensure a smoother and healthier transition from inpatient to
outpatient treatment.
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Conclusion
In summary, we found that most (95.64%) oral antibiotic prescriptions for patients with
suspected UTI were inappropriate, and duration was inappropriate for approximately 40% of the
time. Our findings suggest a greater emphasis of appropriate antibiotic prescribing at hospitals to
reduce possible antibiotic resistance and adverse drug events. Interventions such as antibiotic
stewardship should also be explored, as stewardship programs have been shown to reduce the
percentage of inappropriate antibiotic therapy among patients with suspected urinary tract
infection.
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Appendix
Table 1. Characteristics of hospitalized advanced cancer patients with suspected urinary tract
infection and/or sepsis who have at least one urine culture (n=312).
Characteristics

No. (%) total n= 312

Age, median (IQR) years
Gender, n (%)
Male
Female
Race, n (%)
White
Black
Other
Ethnicity, n (%)
Hispanic
Non-Hispanic
Refused
Length of hospital stay, median (IQR), days
Admission to intensive care unit, n (%)
Selected Comorbidities
Cardiovascular
Endocrine
Neurologic
Pulmonary
Hematology/Oncology
Gastrointestinal
Renal
Musculoskeletal
Infectious disease
Urologic

77.0 (63.75-86.0)
124 (39.74%)
188 (60.26%)
241 (77.24%)
46 (14.74%)
25 (8.02%)
29 (9.29%)
282 (90.38%)
1 (0.32%)
5.0 (3.0-7.0)
73 (23.40%)
40.43%
13.73%
11.55%
8.05%
7.67%
6.63%
5.68%
3.98%
1.14%
1.14%
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Table 2. Most common microbiology organisms in urine culture (n=163).
Organism

N

%

Escherichia coli

80

49.08

Klebsiella species

28

17.18

Proteus species

19

11.66

Enterococcus species

14

8.59

Enterobacter species

8

4.91

Citrobacter species

3

1.84

Pseudomonas aeruginosa

3

1.84

Other gram negative organisms

3

1.84

Serratia marcescens

2

1.23

Staphylococcus aureus

2

1.23

Coagulase negative Staphylococcus

1

0.61
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Figure 1. Antimicrobial susceptibility of ampicillin, cefazolin, ceftriaxone, ciprofloxacin,
nitrofurantoin, TMP-SMX for all isolates and b) for Escherichia coli

a)

b)
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Table 3. Most common mediations during admission and after discharge
Medication during admission

Medication after discharge

Cephalosporin

Cephalosporin

Tetracycline

Fluoroquinolones

Vancomycin

Penicillin

Penicillin

Trimethoprim-sulfamethoxazole

Fluoroquinolones

Tetracycline

Metronidazole

Metronidazole

Other

Other

Trimethoprim-sulfamethoxazole

Macrolide

Nitrofurantoin/Fosfomycin

Methenamine

Aminoglycoside

Vancomycin

Macrolide

Tetracycline

Carbapenem

Clindamycin
Aminoglycoside
Carbapenem
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Table 4. Duration that patients received antibiotics before and after discharge *
Category

During
hospitalization
(median, IQR)

Post discharge
(median, IQR)

Total
(median, IQR)

Urine culture with no
growth
N= 133
*N=28

4.0 (2.0, 6.0)

7.0 (4.0, 15.0)

5.0 (3.0, 8.0)

<100,000 CFU/mL,
no symptoms
N=17
*N=4

3.0 (2.0, 5.0)

5.0 (3.0, 10.0)

7.0 (5.0, 12.0)

Asymptomatic
bacteriuria
N=59
*N=1

4.0 (3.0, 6.0)

5.0 (2.0, 10.75)

7.0 (4.0, 9.5)

10,000-100,000
CFU/mL, 1+
symptoms
N=10

3.0 (2.0, 4.0)

4.0 (1.75, 7.25)

5.5 (5.0, 7.75)

100,000+ CFU/mL,
1+ symptoms
N= 23

4.0 (2.0, 5.0)

5.0 (3.0, 7.0)

9.0 (7.0, 10.0)

UTI
N= 33
*N=4

4.5 (3.0, 5.0)

5.0 (3.0, 8.25)

9.0 (7.0, 15.0)

* Excluded number of patients who did not receive antibiotics

Table 5. Adverse drug events for inappropriate and appropriate antibiotic therapy groups
Category

Re-admissions

Death

CDI

Inappropriate n=263

105 (39.92%)

26 (9.89%)

3 (1.14%)

Appropriate n= 12

6 (50.00%)

1 (8.33%)

0

